Literature DB >> 18164223

Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis.

Claudia Bozzini1, Natascia Campostrini, Paola Trombini, Elizabeta Nemeth, Annalisa Castagna, Ilaria Tenuti, Roberto Corrocher, Clara Camaschella, Tomas Ganz, Oliviero Olivieri, Alberto Piperno, Domenico Girelli.   

Abstract

INTRODUCTION: Insufficient production of hepcidin, the master regulator of iron metabolism, is recognized as the key pathogenetic feature of HFE-related hereditary hemochromatosis (HH). There is a growing interest in measuring the hepcidin levels, which may improve the diagnosis, prognostic evaluation and clinical management of HH. Nevertheless, few investigative tools are available: an immunodot method for urinary hepcidin developed by a single centre (UCLA), not yet ready for large-scale diffusion, and mass spectrometry (MS) based assays, such as surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF-MS). The latter is well suited to small peptides like hepcidin, and can rapidly analyze crude samples with high throughput. This study measured urinary hepcidin levels by SELDI-TOF-MS in a large group of HH patients at diagnosis and during treatment, including both C282Y homozygous and C282Y/H63D compound heterozygotes.
METHODS: We used a protocol based on PBSIIc mass spectrometer and Normal Phase chips. Urinary samples from 30 control subjects were compared to those obtained from 80 HH patients (57 C282Y homozygotes, 23 C282Y/H63D compound heterozygotes). Eighteen C282Y homozygotes and 11 C282Y/H63D compound heterozygotes were analyzed at diagnosis, the remainder during maintenance phlebotomy.
RESULTS: C282Y homozygotes either at diagnosis, or after phlebotomy had significantly lower urinary hepcidin levels than controls (P<0.05). C282Y/H63D compound heterozygotes had hepcidin levels at diagnosis higher than controls, while the hepcidin/ferritin ratio was significantly decreased (P<0.001) suggesting inadequate hepcidin production. After phlebotomy, mean hepcidin levels in the compound heterozygotes were significantly lower than in controls (P<0.001). Samples from 12 randomly selected control subjects were sent to UCLA for duplicate measurement by the immunodot method, yielding a significant correlation (rho=0.64; P=0.024).
CONCLUSIONS: This study supports the use of SELDI-TOF-MS for measuring hepcidin levels in research and clinical applications. Our results in phlebotomized patients suggest that the depletion of iron stores may further exacerbate the HFE-related hepcidin defect.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18164223     DOI: 10.1016/j.bcmd.2007.10.001

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  18 in total

1.  Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization.

Authors:  Joyce J C Kroot; Erwin H J M Kemna; Sukhvinder S Bansal; Mark Busbridge; Natascia Campostrini; Domenico Girelli; Robert C Hider; Vasiliki Koliaraki; Avgi Mamalaki; Gordana Olbina; Naohisa Tomosugi; Chris Tselepis; Douglas G Ward; Tomas Ganz; Jan C M Hendriks; Dorine W Swinkels
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

2.  Presence of hepcidin-25 in biological fluids: bile, ascitic and pleural fluids.

Authors:  Jayantha Arnold; Arvind Sangwaiya; Vijay Manglam; Frank Geoghegan; Mark Thursz; Mark Busbridge
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

3.  Effects of a single dose of oral iron on hepcidin concentrations in human urine and serum analyzed by a robust LC-MS/MS method.

Authors:  Sun-Il Hwang; Yong-Yook Lee; Jung-Ok Park; H James Norton; Elene Clemens; Laura W Schrum; Herbert L Bonkovsky
Journal:  Clin Chim Acta       Date:  2011-08-16       Impact factor: 3.786

4.  Expression of hepcidin and other iron-related genes in type 3 hemochromatosis due to a novel mutation in transferrin receptor-2.

Authors:  Sara Pelucchi; Raffaella Mariani; Paola Trombini; Sabina Coletti; Matteo Pozzi; Valentina Paolini; Donatella Barisani; Alberto Piperno
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

5.  Evaluation of hepcidin isoforms in hemodialysis patients by a proteomic approach based on SELDI-TOF MS.

Authors:  Natascia Campostrini; Annalisa Castagna; Federica Zaninotto; Valeria Bedogna; Nicola Tessitore; Albino Poli; Nicola Martinelli; Antonio Lupo; Oliviero Olivieri; Domenico Girelli
Journal:  J Biomed Biotechnol       Date:  2010-04-15

6.  Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions.

Authors:  Rui Cui; Robert Peter Gale; Guoqing Zhu; Zefeng Xu; Tiejun Qin; Yue Zhang; Gang Huang; Bing Li; Liwei Fang; Hongli Zhang; Lijuan Pan; Naibo Hu; Shiqiang Qu; Zhijian Xiao
Journal:  Leuk Res       Date:  2014-02-10       Impact factor: 3.156

7.  Clinical, pathological, and molecular correlates in ferroportin disease: a study of two novel mutations.

Authors:  Domenico Girelli; Ivana De Domenico; Claudia Bozzini; Natascia Campostrini; Fabiana Busti; Annalisa Castagna; Nadia Soriani; Laura Cremonesi; Maurizio Ferrari; Romano Colombari; Diane McVey Ward; Jerry Kaplan; Roberto Corrocher
Journal:  J Hepatol       Date:  2008-07-17       Impact factor: 25.083

Review 8.  Modern iron replacement therapy: clinical and pathophysiological insights.

Authors:  Domenico Girelli; Sara Ugolini; Fabiana Busti; Giacomo Marchi; Annalisa Castagna
Journal:  Int J Hematol       Date:  2017-12-01       Impact factor: 2.490

9.  HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients.

Authors:  Luca Valenti; Domenico Girelli; Giovanni Francesco Valenti; Annalisa Castagna; Giovanna Como; Natascia Campostrini; Raffaela Rametta; Paola Dongiovanni; Piergiorgio Messa; Silvia Fargion
Journal:  Clin J Am Soc Nephrol       Date:  2009-06-18       Impact factor: 8.237

10.  Reduced serum hepcidin levels in patients with chronic hepatitis C.

Authors:  Domenico Girelli; Michela Pasino; Julia B Goodnough; Elizabeta Nemeth; Maria Guido; Annalisa Castagna; Fabiana Busti; Natascia Campostrini; Nicola Martinelli; Italo Vantini; Roberto Corrocher; Tomas Ganz; Giovanna Fattovich
Journal:  J Hepatol       Date:  2009-08-12       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.